Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan

被引:21
|
作者
Hayashi, Kazuhiko
Katano, Yoshiaki
Takeda, Yasushi
Honda, Takashi
Ishigami, Masatoshi
Itoh, Akihiro
Hirooka, Yoshiki
Nakano, Isao
Yano, Motoyoshi
Goto, Hidemi
Yoshioka, Kentaro
Toyoda, Hidenori
Kumada, Takashi
机构
[1] Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Fujita Hlth Univ, Dept Internal Med, Div Liver & Biliary Dis, Toyoake, Aichi 47011, Japan
[3] Ogaki Municipal Hosp, Dept Gastroenterol, Ogaki, Japan
关键词
genotype; drug-resistance; phylogenetic analysis;
D O I
10.1002/jmv.20824
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis B virus (HBV) has been classified into eight genotypes and can be further divided into several subgenotypes that have different geographic distributions. Because of increased human migration, the prevalence of rare subgenotypes is increasing in Japanese patients with acute hepatitis B. Lamivudine-resistant strains of HBV have begun to emerge in association with chronic hepatitis B. The aim of this study was to investigate the distribution of HBV subgenotypes and lamivudine-resistant strains in patients in Japan with acute hepatitis B. One hundred twenty-three patients with acute hepatitis B and 123 with chronic hepatitis B were studied. HBV subgenotypes and lamivudine-resistance mutations were determined by direct sequencing of the preS and polymerase region, respectively. HBV subgenotypes Aa (n = 3), Ae (n = 23), Ba (n = 7), Bi (n = 3), Cs (n = 7), Ce (n = 76), D (n = 2), and H (n = 2) were detected in patients with acute hepatitis. In patients with chronic hepatitis, HBV subgenotypes Ae (n = 4), Ba (n = 1), Bj (n = 18), and Ce (n = 100) were found. Non-common Japanese subgenotypes, that is, non-Bj and non-Ce, were detected more frequently in patients with acute hepatitis (35.8%) than in patients with chronic hepatitis (4.1%) (Odds ratio, 0.076; 95% Cl, 0.029-0.200; P < 0.0001). Lamivudine-resistance mutations were detected in chronic hepatitis patients with breakthrough hepatitis but not in other patients. In conclusion, the prevalence of uncommon Japanese HBV subgenotypes is expected to increase, although larnivudine-resistant strains have not yet been found in patients with acute hepatitis B.
引用
收藏
页码:366 / 373
页数:8
相关论文
共 50 条
  • [21] Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
    Park, Chan Ho
    Jung, Seok Won
    Shin, Jung Woo
    Bae, Mi Ae
    Lee, Yoon Im
    Park, Yong Tae
    Chung, Hwa Sik
    Park, Neung Hwa
    CLINICAL AND MOLECULAR HEPATOLOGY, 2016, 22 (01) : 152 - 159
  • [22] Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B
    Peters, MG
    Hann, HW
    Martin, P
    Heathcote, EJ
    Buggisch, P
    Rubin, R
    Bourliere, M
    Kowdley, K
    Trepo, C
    Gray, DF
    Sullivan, M
    Kleber, K
    Ebrahimi, R
    Xiong, S
    Brosgart, CL
    GASTROENTEROLOGY, 2004, 126 (01) : 91 - 101
  • [23] Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients
    Pollicino, Teresa
    Isgro, Graziella
    Di Stefano, Rosa
    Ferraro, Donatello
    Maimone, Sergio
    Brancatelli, Santa
    Squadrito, Giovanni
    Di Marco, Vito
    Craxi, Antonio
    Raimondo, Giovanni
    ANTIVIRAL THERAPY, 2009, 14 (05) : 649 - 654
  • [24] Predictors of a pejorative outcome in patients treated with adefovir dipivoxil for reactivation of chronic hepatitis B due to lamivudine-resistant hepatitis B virus mutants
    Consigny, Y
    Plessier, A
    Martinot, M
    Pham, BN
    Castelnau, C
    Paradis, V
    Durand, E
    Degos, E
    Valla, D
    Marcellin, P
    JOURNAL OF HEPATOLOGY, 2005, 42 : 173 - 174
  • [25] Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
    Ming-Tsung Lin
    Yeh-Pin Chou
    Tsung-Hui Hu
    Hsien-Chung Yu
    Yu-Chun Hsu
    Ming-Chao Tsai
    Po-Lin Tseng
    Kuo-Chin Chang
    Yi-Hao Yen
    King-Wah Chiu
    Archives of Virology, 2014, 159 : 29 - 37
  • [26] Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
    Lin, Ming-Tsung
    Chou, Yeh-Pin
    Hu, Tsung-Hui
    Yu, Hsien-Chung
    Hsu, Yu-Chun
    Tsai, Ming-Chao
    Tseng, Po-Lin
    Chang, Kuo-Chin
    Yen, Yi-Hao
    Chiu, King-Wah
    ARCHIVES OF VIROLOGY, 2014, 159 (01) : 29 - 37
  • [27] Lamivudine and famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation
    Panos, George Z.
    Lampropoulos, Konstantinos M.
    Angelousi, Anna G.
    Charatsis, Gerasimos G.
    Falagas, Matthew E.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (02) : 222 - 223
  • [28] Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan
    Ito, Kiyoaki
    Yotsuyanagi, Hiroshi
    Sugiyama, Masaya
    Yatsuhashi, Hiroshi
    Karino, Yoshiyasu
    Takikawa, Yasuhiro
    Saito, Takafumi
    Arase, Yasuji
    Imazeki, Fumio
    Kurosaki, Masayuki
    Umemura, Takeji
    Ichida, Takafumi
    Toyoda, Hidenori
    Yoneda, Masashi
    Tanaka, Yasuhito
    Mita, Eiji
    Yamamoto, Kazuhide
    Michitaka, Kojiro
    Maeshiro, Tatsuji
    Tanuma, Junko
    Korenaga, Masaaki
    Murata, Kazumoto
    Masaki, Naohiko
    Koike, Kazuhiko
    Mizokami, Masashi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (01) : 180 - 189
  • [29] Resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B.
    Osiowy, C
    Heathcote, J
    Zoulim, F
    Willems, B
    Villeneuve, JP
    HEPATOLOGY, 2005, 42 (04) : 586A - 587A
  • [30] Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B
    Santantonio, Teresa
    Fasano, Massimo
    Durantel, Sandra
    Barraud, Luc
    Heichen, Manuela
    Guastadisegni, Angela
    Pastore, Giuseppe
    Zoulim, Fabien
    ANTIVIRAL THERAPY, 2009, 14 (04) : 557 - 565